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A B S T R A C T
Background
Venous leg ulcers (VLUs) or varicose ulcers are the final stage of chronic venous insufficiency (CVI), and are the most common type
of leg ulcer. The development of VLUs on ankles and lower legs can occur spontaneously or after minor trauma. The ulcers are often
painful and exudative, healing is often protracted and recurrence is common. This cycle of healing and recurrence has a considerable
impact on the health and quality of life of individuals, and healthcare and socioeconomic costs. VLUs are a common and costly problem
worldwide; prevalence is estimated to be between 1.65% to 1.74% in the western world and is more common in adults aged 65
years and older. The main treatment for a VLU is a firm compression bandage. Compression assists by reducing venous hypertension,
enhancing venous return and reducing peripheral oedema. However, studies show that it only has moderate effects on healing, with
up to 50% of VLUs unhealed after two years of compression. Non-adherence may be the principal cause of these poor results, but
presence of inflammation in people with CVI may be another factor, so a treatment that suppresses inflammation (healing ulcers more
quickly) and reduces the frequency of ulcer recurrence (thereby prolonging time between recurrent episodes) would be an invaluable
intervention to complement compression treatments. Oral aspirin may have a significant impact on VLU clinical practice worldwide.
Evidence for the effectiveness of aspirin on ulcer healing and recurrence in high quality RCTs is currently lacking.
Objectives
To assess the benefits and harms of oral aspirin on the healing and recurrence of venous leg ulcers.
Search methods
InMay 2015we searched:TheCochraneWounds SpecialisedRegister; TheCochraneCentral Register ofControlledTrials (CENTRAL)
(TheCochrane Library); OvidMEDLINE;OvidMEDLINE (In-Process&OtherNon-IndexedCitations);Ovid EMBASE andEBSCO
CINAHL. Additional searches were made in trial registers and reference lists of relevant publications for published or ongoing trials.
There were no language or publication date restrictions.
Selection criteria
We included randomised controlled trials (RCTs) that compared oral aspirin with placebo or no drug intervention (in the presence or
absence of compression therapy) for treating people with venous leg ulcers. Our main outcomes were time to complete ulcer healing,
rate of change in the area of the ulcer, proportion of ulcers healed in the trial period, major bleeding, pain, mortality, adverse events
and ulcer recurrence (time for recurrence and proportion of recurrence).
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Data collection and analysis
Two review authors independently selected studies for inclusion, extracted data, assessed the risk of bias of each included trial and
assessed overall quality of evidence for the main outcomes in the ’Summary of findings’ table.
Main results
The electronic search located 62 studies. We included two RCTs of oral aspirin (300 mg/daily) given in addition to compression
compared with compression and placebo, or compression alone. To date, the impact of aspirin on VLUs has been examined by only
two randomised clinical trials, both with a small number of participants. The first RCT was conducted in the United Kingdom (n=20)
and reported that daily administration of aspirin (300mg) in addition to compression bandages increased both the rate of healing, and
the number of participants healed when compared to placebo in addition to compression bandaging over a four month period. Thirty-
eight per cent of the participants given aspirin reported complete healing compared with 0% in the placebo group . Improvement
(assessed by reduction in wound size) occurred in 52% of the participants taking aspirin compared with 26% in those taking placebo).
The study identified potential benefits of taking aspirin as an adjunct to compression but the sample size was small, and neither the
mechanism by which aspirin improved healing nor its effects on recurrence were investigated.
In 2012 an RCT in Spain (n=51) compared daily administration of aspirin (300mg) in addition to compression bandages with
compression alone over a five month period. There was little difference in complete healing rates between groups (21/28 aspirin and
17/23 compression bandages alone) but the average time to healing was shorter (12 weeks in the treated group vs 22 weeks in the
compression only group) and the average time for recurrence was longer in the aspirin group (39 days: [SD 6.0] compared with 16.3
days [SD 7.5] in the compression only group). Although this trial provides some limited data about the potential use of aspirin therapy,
the sample size (only 20 patients) was too small for us to draw meaningful conclusions. In addition, patients were only followed up for
4 months and no information on placebo was reported.
Authors’ conclusions
Low quality evidence from two trials indicate that there is currently insufficient evidence for us to draw definitive conclusions about
the benefits and harms of oral aspirin on the healing and recurrence of venous leg ulcers. We downgraded the evidence to low quality
due to potential selection bias and imprecision due to the small sample size. The small number of participants may have a hidden real
benefit, or an increase in harm. Due to the lack of reliable evidence, we are unable to draw conclusions about the benefits and harms
of oral daily aspirin as an adjunct to compression in VLU healing or recurrence. Further high quality studies are needed in this area.
P L A I N L A N G U A G E S U M M A R Y
Oral aspirin for venous leg ulcers
Background
Venous leg ulcers (VLUs) are the most common type of leg ulcers (sores) and are caused by poor blood flow in the veins of the legs
(chronic venous insufficiency). Chronic venous insufficiency leads to high blood pressure in the veins (venous hypertension), which
triggers many alterations in the skin of the leg. Leg ulcers are the end stage of these alterations. VLUs can occur spontaneously or after
minor trauma, they are often painful and produce heavy exudation (loss of fluid). VLUs are a major health problem because they are
quite common, tend to become chronic (long-lasting) and also have a high tendency to recur. They affect older people more frequently,
have high costs of care, and a high individual and social burden for those affected.
Compression therapy, in the form of a firm bandage over the leg, which aids the flow of blood in the veins, is a well-established treatment
for VLUs. However, studies show that compression has only moderate effects on healing, with up to 50% of VLUs remaining unhealed
after two years of compression, possibly due to a prolonged inflammation process. A better understanding of the degenerative changes
in the skin of the leg in people with VLUs and the chronic inflammation process involved in them, has led researchers to test different
medicines that could improve the treatment of this condition. Aspirin has some well-known properties including: pain relief (analgesic),
reducing inflammation and fever, and stopping blood cells from clumping together, which prevents formation of blood clots. Aspirin
therapy may improve time to healing and decrease the number of recurrent VLU episodes. If proved effective, the low cost of aspirin
therapy as an adjunct to compression would make it an affordable preventive agent for people with VLUs in all countries.
Review question
What are the benefits and harms of oral aspirin on the healing and recurrence of venous leg ulcers.
2Oral aspirin for treating venous leg ulcers (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
What we found
We identified only two randomised controlled trials that compared oral aspirin (300mg daily) plus compression with compression and
placebo, or compression alone. One study conducted in UK included 20 participants (ten in the aspirin group and ten in the control
group) and followed people for four months. This trial reported that the ulcer area had reduced (by 6.5 cm², a 39.4% reduction) in the
aspirin group compared with no reduction in ulcer area in the control group, and that a higher proportion of the ulcers (38%) in the
aspirin group had completely healed compared with none in the control group. Recurrence was not investigated in this study. Another
study conducted in Spain included 51 participants (23 in the aspirin group and 28 in the control group) and followed people until
their ulcers had healed. The study reported that the average time for healing was 12 weeks in the aspirin group and 22 weeks in the
control group, and that there was no real difference between the proportion of people with ulcers healed (17 (74%) out 23 people in
the aspirin group and 21 (75%) out 28 people in the control group). The average time for recurrence was longer in the aspirin group
(39 days) compared with (16.3 days) in group of compression alone. Adverse events were not reported in either trial.
We considered these two studies too small and low quality for us to draw definitive conclusions about the benefits and harms of oral
aspirin on the healing and recurrence of venous leg ulcers. The UK study provides only limited data about the potential benefits of
daily oral aspirin therapy with compression due to a small sample size of only 20 participants and short follow up. The Spanish study
provides limited data on 51 participants comparing aspirin and compression to a control group. The fact that no information was
reported regarding placebo in the control group means the estimate of effect is uncertain. Further high quality studies are needed in
this area.
This plain language summary is up to date as of 27 May 2015.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oral aspirin for venous leg ulcers
Patient or population: pat ients with venous leg ulcers
Settings: hospital outpat ients in UK and Spain
Intervention: oral aspirin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Oral aspirin
Average time for ulcer
healing
22 weeks 12 weeks Not est imable 51 (1 study) ⊕⊕©©
low1,2
P values and conf idence
intervals were not re-
ported
Reduction of ulcer area
(median)
0 cm² 6.5cm² Not est imable 20
(1 study)
⊕⊕©©
low2,3
P value < 0.002
Follow-up: 4 months
Proportion of healed
ulcers in the trial pe-
riod
No healed ulcers 38% of healed ulcers Not est imable 20
(1 study)
⊕⊕©©
low2,3
P value < 0.007
Follow-up: 4 months
M ajor bleeding See comment See comment Not est imable 20
(1 study)
⊕⊕©©
low2,3
No events were ob-
served in either group,
follow-up: 4 months
Another study reported
2 hospitalisat ions for
unknown reasons, inter-
vent ion group not spec-
if ied
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Average time of ulcer
recurrence
16.33 days
SD: 7.5
39 days
SD: 6.0
Not est imable 51
(1 study)
⊕⊕©©
low1,2
P value = 0.007
Post hoc assessment
not pre-specif ied in pro-
tocol
M ortality See comment See comment Not est imable See comment See comment Mortality not reported
Other adverse events See comment See comment Not est imable 71
(2 study)
See comment No events were ob-
served in either group.
del Río Solá reported
2 hospitalisat ions for
unknown reasons, the
group of these pat ients
were not specif ied and
they were removed f rom
the study
* The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval)
is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io; SD: standard deviat ion
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
1 Allocat ion concealment and blinding of outcome assessment were not described. Part icipants and personnel were not
blinded. There was a high risk of bias f rom incomplete outcome data.There were some inconsistencies in the report ing of
the data
2 The study results are based on one small study with insuf f icient data to est imate the ef fect precisely
3 Select ion, performance and report ing biases were unclear
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B A C K G R O U N D
Description of the condition
Venous leg ulcers (VLUs; also known as varicose ulcers or stasis
ulcers) occur as results of the chronic venous insufficiency (CVI),
which is a functional disorder of the venous system of the leg. The
venous leg system is a compound of superficial, deep and perfo-
rating veins (perforating veins connect the superficial and deep
veins). Damage in any of these veins causes an impairment of ve-
nous return, this impairment causes increased venous pressure also
known as venous hypertension Ballard 2000). Chronic venous hy-
pertension (CVH) leads to an inflammatory response by leuko-
cytes (white blood cells involved in the inflammation process) that
causes cellular and tissue dysfunction which in turn results in vari-
cose veins (veins unnaturally and permanently distended) and der-
mal changes called lipodermatosclerois characterised by the pres-
ence of oedema, hyperpigmentation, induration and eczema of the
skin. Ulceration is the final stage of these alterations. (Appendix
1; Thomas 1988; De Araujo 2003; Barron 2007; Rafetto 2009).
Clinically, a VLU is characterised by erosion of the skin usually in
the gaiter area of the lower leg (between the knee and the ankle;
Dorland 2007). Ulcers vary in size and number. Usually, they have
a shallow base, flat margin with the surrounding skin showing
features of CVH (Gilliland 1991; Valencia 2001; Raju 2009).
Pain that impairs quality of life is present in 75% of people with
this condition (Friedman 1990; Philips 1994); in some cases the
ulcer has an associated odour that can result in social isolation and
depression (Gilliland 1991;Jones 2008).
Venous leg ulceration has a tendency to become chronic and re-
current; one estimate suggests that 30% of healed ulcers recur in
the first year, rising to 78% after two years (Mayer 1994). Around
80% of lower extremity leg ulcers presenting in general practice are
VLUs; the remaining 20% are as a result of arterial insufficiency,
neuropathy, trauma, inflammatory or metabolic conditions, ma-
lignancy and infections (Falabella 1998; Sibbald 1998; Valencia
2001; Moloney 2004; Dealey 2005). Diagnosis of a VLU is based
on a clinical assessment and the presence of symptoms that are
consistent with venous hypertension (i.e. an ulcer located in the
medial gaiter area; presence of varicose veins, eczema, pigmenta-
tion, induration and oedema, in any combination). In a few cases
the diagnosis can be complemented by non-invasive methods such
as ultrasonography.
VLUs are a major health problem because of their frequent occur-
rence and associated high cost of care. The disease mainly affects
people between 60 and 80 years of age, women are affected three
times more frequently than men. The rate of occurrence of VLUs
is likely to increase as the average age of the population increases
(Callam 1987; Margolis 2002). Estimates of its occurrence rate
vary by country. For example, in Europe, including countries such
as Denmark, Czechoslovakia and Switzerland, the rates of occur-
rence have been reported at 1% to 5.5% in women and 0.9% to
1.9% in men (Bobek 1966; Arnoldi 1968; Kamber 1978); in the
USA the rates were reported as 0.2% in women and 0.1% in men
(Coon 1973); and in Brazil as approximately 1.5% for open or
healed VLU (Maffei 1986). The cost of treating VLUs is estimated
to be one billion USD per year in the USA, and the average cost
for one person over a lifetime has been estimated to exceed USD
40,000 (Valencia 2001). Another study of people with VLUs es-
timated that the average duration of follow-up was 119 days and
the average total medical cost per person was USD 9685 (Olin
1999).
Description of the intervention
The goals of treatment for people with venous leg ulcers include:
reduction of oedema, relief of pain and lipodermatosclerosis, ulcer
healing, and prevention of recurrence (DeAraujo 2003). Different
modalities of treatment are used for treating VLUs and these are
sometimes used in combination (Blankensteijn 2009). The most
common form of treatment is compression therapy (covering the
leg with a firm bandage or socks, to apply an external force which
aids the flow of blood in the veins). Whilst compression has the
potential to heal approximately 50% of VLUs (Weller 2012), rest
with elevation of the affected leg, venous surgery, and oral medica-
tion with drugs (such as pentoxifylline that aim to improve blood
flow and reduce clotting (Jull 2007)) are also used to treat this
condition. A treatment that can suppress inflammation would be
useful. Oral aspirin is a widely used drug that may have the po-
tential to exert a beneficial influence in the treatment of VLUs.
However, until now, no comprehensive summary of the available
evidence has been conducted.
How the intervention might work
Classical signs of inflammation have been observed in biopsies and
plasma samples in experimentalmodels of venous disease. The cas-
cade starts with increased vascular permeability (increased leakage
of plasma and cells through the vein wall) and progression to adhe-
sion of leukocytes (white blood cell involved in the inflammation
process) and platelets (very small structures shaped like a discus,
present in the blood with important role in the coagulation) to
endothelium (the cells lining the lumen of the veins). Over time
the disease progresses to vascular restructuring of venous varicosi-
ties (veins which are unnaturally and permanently distended). Un-
like acute wound healing, chronic VLUs remain at an prolonged
inflammatory stage with formation of granulation tissue (newly
formed tissue which repairs damaged areas) (Bergan 2007).
Aspirin or acetylsalicylic acid was introduced as a medication in
1899 by Dreser (Burke 2006). Aspirin has analgesic, anti-inflam-
matory and antipyretic (fever-reducing) properties (Winter 1966).
It inhibits platelet aggregation, and acts as an inhibitor of cyclooxy-
genase (substance involved in the synthesis prostaglandins), result-
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ing in the inhibition of the biosynthesis (physiologic production
of a substance into the body) of prostaglandins (substances in-
volved in the inflammatory process causing venous dilatation and
inhibition the platelet aggregation) (Salzman 1971; Vane 1971).
Prostaglandins are released during the inflammatory phase, and are
thought to increase blood vessel permeability, manifested by ve-
nous oedema and capillary leakage. Aspirin stimulates the biosyn-
thesis of other anti-inflammatory compounds by inhibiting the
cyclooxygenase pathway. The precise mechanism by which aspirin
is thought to mediate effects on VLU healing is unclear, although
inhibition of platelet activation and reduction of inflammation
and pain have been suggested (Ibbotson 1995; De Araujo 2003).
However, aspirin is known to have adverse effects, most commonly
gastric ulceration and other gastrointestinal effects, as well as hep-
atotoxicity (liver damage), exacerbation of asthma, skin rashes and
renal toxicity (Cappelleri 1995; Burke 2006).
Why it is important to do this review
Chronic VLU healing remains a complex clinical problem and
requires the intervention of skilled, but costly, multidisciplinary
wound care teams. Recurrence is often an ongoing issue for peo-
ple who experience venous ulcers. Aspirin is an inexpensive and
widely available treatment currently used in several other clinical
situations. Oral aspirin is potentially one of the most effective pre-
ventive agents for use in people with VLUs. It has the potential
to improve healing rates, shorten time to healing and decrease the
number of recurrent episodes after healing. If proved effective, the
low cost of aspirin therapy as an adjunct to compression would
make it an affordable preventive agent for people with VLUs in
all countries. Despite its potential benefits, there are limited data
available about the effectiveness of aspirin in people with VLUs.
Additionally, with the number of people with VLUs expected to
rise significantly in the coming decades, development of new safe
ways of healing and reducing recurrence are high priorities in
health research.
O B J E C T I V E S
To assess the benefits and harms of oral aspirin on the healing and
recurrence of venous leg ulcers.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of oral aspirin to treat people
with venous leg ulcers.
Types of participants
Adults (as defined in trials) undergoing treatment for venous leg
ulceration or prevention of recurrence of venous leg ulcers.
Types of interventions
Oral aspirin compared with placebo or any other therapy in the
presence or absence of compression therapy.
To be eligible for inclusion, treatment with oral aspirin must be
the only systematic difference between treatment arms, therefore
a study in which one group received compression and one did not
would not be eligible for inclusion unless within a factorial design.
Types of outcome measures
Primary outcomes
• Time to complete ulcer healing.
• Rate of changes in the area of the ulcer in the trial period.
• Proportion of ulcers healed in the trial period.
• Proportions of people with ulcers completely healed in the
trial period.
• Major bleeding (haemorrhagic stroke, gastric bleeding, any
bleeding requiring blood transfusion, any bleeding causing
hospitalisation).
Secondary outcomes
• Pain relief (as measured by a valid pain scale).
• Mortality from any cause.
• Any adverse events (e.g. renal failure, neutropenia, low
platelets level, gastric complaints, diarrhoea, skin rash, minor
bleeding).
• Ulcer recurrence (time to recurrence and proportion of
people with recurrence).
Search methods for identification of studies
Electronic searches
We searched the following electronic databases to identify reports
of randomised controlled trials:
• The Cochrane Wounds Specialised Register (searched 27
May 2015);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2015, Issue 4);
• Ovid MEDLINE (1946 to 26 May 2015);
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• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations) (searched 26 May 2015);
• Ovid EMBASE (1974 to 26 May 2015);
• EBSCO CINAHL (1982 to 27 May 2015).
The search strategies we used can be found in Appendix 2. The
Ovid MEDLINE searches were combined with the Cochrane
Highly Sensitive Search Strategy for identifying randomised tri-
als in MEDLINE: sensitivity- and precision-maximizing version
(2008 revision) (Lefebvre 2011). We combined the EMBASE
search with the Ovid EMBASE trial filter terms developed by
the UK Cochrane Centre (Lefebvre 2011). We combined the
CINAHL search with the trial filter developed by the Scottish
Intercollegiate Guidelines Network (SIGN 2011). There was no
restriction on the basis of date, or language of publication.
We also searched the following clinical trials registries:
ClinicalTrials.gov (https://clinicaltrials.gov/);
WHO International Clinical Trials Registry Platform (ICTRP) (
http://apps.who.int/trialsearch/default.aspx).
Searching other resources
We searched the references of all identified studies in order to find
any further relevant trials. We also contacted experts in the field.
Data collection and analysis
Selection of studies
Two reviews authors (NGMandRFA) selected studies as described
in Chapter 7 of theCochrane Handbook for Systematic Reviews of
Interventions as follows (Higgins 2011a):
• We merged search results using reference management
software, and removed duplicate records of the same report.
• We examined titles and abstracts to remove obviously
irrelevant reports.
• We retrieved full text of the potentially relevant reports.
• We linked multiple reports of the same study.
• We examined full-text reports for compliance of studies
with eligibility criteria.
• We clarified study eligibility (where appropriate) by
corresponding with investigators.
• We made final decisions on study inclusion to allow data
collection to proceed.
Any disagreements were solved by discussion. If this did not result
in agreement, the opinion of the third review author (PEdOC)was
decisive. We documented the reasons for exclusion of any article.
Data extraction and management
Two reviews authors (NGM and RFA) independently extracted
details of eligible studies and summarised themusing a data extrac-
tion sheet specific to this review that was constructed according
Chapter 7 of the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011a). The data extracted included the base-
line characteristics of the intervention and control group partici-
pants, and included (where available): participant numbers, age,
gender, ethnicity, the main outcome measures, length of follow-
up, and numbers of drop-outs (Table 1).
Assessment of risk of bias in included studies
We used the Cochrane tool for assessing risk of bias to present a
summary of the risk of bias for each included study . This tool
addresses seven specific domains Higgins 2011b:
• Was the allocation sequence adequately generated?
• Was the allocation adequately concealed?
• Was the blinding of participants and personnel adequately
provided?
• Was the blinding of outcome assessors adequately provided?
• Were incomplete outcome data adequately addressed?
• Were reports of the study free of suggestion of selective
outcome reporting?
• Was the study apparently free of other problems that could
put it at a high risk of bias?
Two authors (NGM and RFA) assessed each study independently;
disagreements were solved by consultation with the third review
author (PEdOC). Additionally, we presented a ’Risk of bias’ sum-
mary figure, reporting all our judgements in a cross-tabulation of
study by entry (Figure 1). This display of internal validity shows
the weight given to the results of the particular studies.
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Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Measures of treatment effect
For binary outcomes (e.g. recurrence, improvement), we planned
to present risk ratios (RR); risk differences (RD), the number
needed to treat for an additional beneficial outcome (NNTB), and
the number needed to treat for an additional harmful outcome
(NNTH), all with corresponding 95% confidence intervals (CI).
For continuous data (e.g. ulcer area), we planned to present differ-
ences as mean differences (MD) with corresponding 95% CIs, or
standardised mean differences (SMD) when the studies assessed
the same outcome but measured it in a variety of ways (e.g. dif-
ferent questionnaires for pain assessment).
For time to complete ulcer healing, that is time-to-event data,
we planned to use the most appropriate way of summarising this
type of data using survival analysis methods and to express the
intervention effect as a hazard ratio (HR).
Unit of analysis issues
We only considered simple parallel-group designs for clinical trials
(Deeks 2011). If healing outcomes were reported at several time
points, we planned to perform the analysis using the time-points
reported (for example, 30 or 60 days or the time for ulcer healing).
We planned to consider the number of ulcers per patient and the
ulcer area per patient, which means, for patients with more than
one ulcer, calculating the total area of the ulcers.
Dealing with missing data
We contacted the trial authors to obtain relevant missing data and
investigated attrition rates (for example, drop-outs, losses to fol-
low-up andwithdrawals). Authors did not respond to our requests.
We address the potential impact of missing data on the findings
of the review in the discussion section (Higgins 2011c).
Assessment of heterogeneity
We planned to assess statistical heterogeneity using the I² statistic
to examine the percentage of total variation across studies due to
heterogeneity rather than to chance (Higgins 2003). Values of I²
under 40% indicate a low level of heterogeneity and justify the
use of a fixed-effect model for meta-analysis. Values of I² between
30% and 60% are considered to indicate moderate heterogeneity
and a random-effects model would have been used. Values of I²
higher than 60% indicate a high level of heterogeneity; in which
casemeta-analysis would not be appropriate.We planned to report
whether statistical, methodological and clinical heterogeneity were
present (Deeks 2011).
Assessment of reporting biases
If a sufficient number of studies had been eligible for inclusion
(more than 10), we planned to use funnel plots to assess for the
potential existence of small study bias. There are a number of
explanations for the asymmetry of a funnel plot and we planned
to interpret the results (Egger 1997).
Data synthesis
In the absence of heterogeneity, we planned to use a fixed-effect
model for meta-analysis. If statistical heterogeneity was moder-
ate (I² between 30% and 60%), we planned to use a random-
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effects model. In the presence of substantial statistical heterogene-
ity between studies, we planned to present a narrative summary
(O’Rourke 1989).
’Summary of findings’ tables
We planned to present the main results of the review in ’Summary
of findings’ tables. These tables present key information concern-
ing the quality of the evidence, the magnitude of the effects of
the interventions examined and the sum of available data for the
main outcomes (Schunemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of the main outcomes using the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) approach.
The GRADE approach defines the quality of a body of evidence
as the extent to which one can be confident that an estimate of
effect or association is close to the true quantity of specific interest.
The quality of a body of evidence involves consideration of within
trial risk of bias (methodological quality), directness of evidence,
heterogeneity, precision of effect estimates and risk of publication
bias (Schunemann 2011b). We planned to present the following
outcomes in the ’Summary of findings’ tables.
• Time to complete ulcer healing.
• Rate of changes in the area of the ulcer in the trial period.
• Proportion of ulcers healed in the trial period.
• Major bleeding (haemorrhagic stroke, gastric bleeding, any
bleeding requiring blood transfusion, any bleeding causing
hospitalisation).
• Mortality from any cause.
• Any adverse events (e.g. renal failure, neutropenia, low
platelets level, gastric complaints, diarrhoea, skin rash, minor
bleeding).
• Ulcer recurrence (time to recurrence and proportion of
people with recurrence).
Sensitivity analysis
Weplanned to perform sensitivity analyses to explore the influence
of the following factors on the effect of aspirin:
• repeating the analysis excluding unpublished studies;
• repeating the analysis taking into account risk of bias: we
planned to exclude those studies at high risk of bias (i.e. those
lacking adequate sequence generation, unclear allocation
concealment and no blinding of outcome assessment).
We also planned to test the robustness of the results by repeating
the analysis using different measures of effect size (risk ratio, odds
ratio, etc.) and different statistical models (fixed-effect and ran-
dom-effects models; (Deeks 2011).
R E S U L T S
Description of studies
Results of the search
The electronic search identified 62 studies; no studies were found
through additional searching strategies (such as contact with ex-
perts and checking the references of studies ). After the anal-
ysis of title and abstracts, we excluded 59 studies as they did not
meet the inclusion criteria.Three RCTs were selected for full-text
analysis: Layton 1994; Ibbotson 1995 and del Río Solá 2012. Af-
ter the full-text analysis, two RCTs were included in the review
(Layton 1994; del Río Solá 2012). Ibbotson 1995 used the same
people and data as the Layton RCT but compared them with a
control group of healthy people, so we excluded this trial (Figure
2).
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Figure 2. Flow diagram of included and excluded studies
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Included studies
Details of the included studies are summarised in Characteristics
of included studies Table 1.
Layton 1994 reported a single-centre parallel RCT (20 partici-
pants) that evaluated daily administration of oral aspirin (300 mg)
in addition to compression, compared to placebo and compres-
sion. Participants were recruited from the Academic Unit of Der-
matology, General Infirmary at Leeds, West Yorkshire, UK. del
Río Solá 2012 reported a single-centre parallel RCT (51 partici-
pants) that evaluated daily administration of oral aspirin (300 mg)
in addition to compression compared to compression only and re-
cruited from the Department of Angiology and Vascular Surgery,
University Hospital of Valladolid, Spain, from December 2001 to
September 2005.
Layton 1994 was a prospective trial that included 20 people with
venous leg ulcers 2 cm or larger, divided into two parallel groups:
10 participants received oral aspirin (300 mg/day) plus compres-
sion therapy compared with 10 who received placebo plus com-
pression therapy.
The del Río Solá 2012 study was a prospective trial that included
51 people with venous leg ulcers 2 cm or larger, divided into
two parallel groups: 23 participants received oral aspirin (300 mg/
day) plus compression therapy compared with 28 who received
compression therapy alone.
The source of funding was not reported for either trial.
Both RCTs used the same intervention (oral aspirin 300 mg/day).
The Layton 1994 study randomized participants to a placebo as
an adjunct to compression therapy in the control group, while the
del Río Solá 2012 study randomized those in the control group
to compression therapy alone (no placebo). Compression ther-
apy consisted of high compression (Setopress) in the Layton 1994
RCT. The del Río Solá 2012 RCT did not specify what type of
compression was used, although the trialists reported the applica-
tion of a two-layer system consisting of one layer of padding and
one layer of compression bandage.
The Layton 1994 trial followed participants for four months and
then stopped the trial. The results were expressed in terms of re-
duction of the ulcers’ size (surface area cm²) and proportions of
ulcers completely healed in the trial period.
The del Río Solá 2012 trial followed participants until their ulcers
had healed completely. The results were expressed in terms of
proportion of healed ulcers in each group and average time for
ulcer healing. . After healing, they continued to follow participants
to analyse the proportion of ulcer recurrence and time until ulcer
recurrence.
Excluded studies
We excluded the Ibbotson 1995 trial. This trial used the same
participants reported in Layton 1994 and compared them with a
control group of healthy people without venous leg ulcers. The
objective was to evaluate some haemostatic parameters in people
with venous leg ulcers taking oral aspirin (see Characteristics of
excluded studies).
Ongoing studies
We identified three ongoing studies which evaluate the benefits
and harms of aspirin in people with VLUs. (Characteristics of
ongoing studies).
Low dose aspirin for venous leg ulcers in NZ (Aspirin4VLU)
(NCT02158806) is a prospective, randomised, double blinded,
2 groups in parallel study that will evaluate whether aspirin (150
mg) once daily for up to 24 weeks improves time to healing when
compared to placebo once daily for up to 24 weeks as an ad-
junct to compression. NCT02333123 is leading a phase II ran-
domised, double blind, parallel group, placebo-controlled efficacy
trial taking place in the UK. The Aspirin for Venous Ulcer Ran-
domised Trial (AVURT) will evaluate if aspirin 300 mg once daily
for up to 27 weeks added to compression improves time to heal-
ing when compared to placebo once daily for up to 27 weeks.
ACTRN12614000293662 is investigating the clinical effective-
ness of aspirin as an adjunct to compression therapy in healing
chronic venous leg ulcers: a randomised double-blinded placebo-
controlled trial in Australia. The ASPiVLU study will compare if a
daily dose of 300 mg enteric coated aspirin as an adjunct to com-
pression for 24 weeks improves time to healing when compared
to a placebo. Recruitment has commenced for all three trials.
Risk of bias in included studies
See Figure 1 and Summary of findings for the main comparison.
Allocation
The Layton 1994 trial was described as ’randomized’ but did not
report the method of randomizations or the concealment of allo-
cation. In del Río Solá 2012, randomization was undertaken by an
independent researcher using a computer program, but allocation
concealment was not described.
Blinding
The Layton 1994 trial compared oral aspirin with placebo, and
the trial was described as ’double-blinded’, but the trialists did not
describe theirmethods. The evaluation of ulcer size was conducted
by planimetry of photographs taken in standardized conditions,
so we judged this as low risk of bias.
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The del Río Solá 2012 trial did not use a placebo but compared in-
tervention (aspirin) with no intervention. In this scenario, blind-
ing of participants and personnel was not possible. The study re-
ported information about ulcer development (size, epithelization)
weekly in a specific data sheet, but they did not describe who did
what and how this work was done, so we judged this study as high
risk of bias.
Incomplete outcome data
The Layton 1994 trial did not have any withdrawals. The del
Río Solá 2012 trial reported four withdrawals, two from each
group. Two of these four participants were withdrawn because
they needed to be in hospital, but the cause and group assignments
were not reported.
Selective reporting
As there were several inconsistencies in the del Río Solá 2012
report, we assigned the study a low risk of reporting bias. Time for
complete ulcer healing in the control group, which was stated as
22 weeks in the text but as 16.5 weeks in the table (Table I of the
study); errors with the numbers of people in each group, which
were reported as 23 for the aspirin group and 28 for the control
group in themain text, but appeared as 20 and 31 in the table; and
the proportion of people completely healedwas reported as 0.73%
rather than 75% (21 out of 28 people) for the control group and
0.75% rather than 74% (17 out of 23 people) for the treatment
group.
As the results of both prespecified primary outcomeswere reported
in Layton 1994, we judged it to be free of selective reporting.
Other potential sources of bias
The Layton 1994 trial was stopped in the fourth month. In that
time, 38% of ulcers had healed in the aspirin group, but no ulcers
had healed in the placebo group. However, the time period could
be considered too short, as the assumption that all ulcers could
heal in this period may lead to misinterpretation (i.e. some ulcers
may have healed in the control group given more time).
In the del Río Solá 2012 trial, despite an appropriate method of
randomizations (an independent researcher and computer pro-
gram), the generated groups were different in relation to the length
of time that people had ulcers before treatment. ’Young’ ulcers
predominated in the aspirin group, and may have had a tendency
to heal faster than chronic or ’older’ ulcers. Also, the trial authors
did not determine a specific trial period. To calculate the size of the
study, they used an expected difference of 45% between groups,
but did not specify whether the difference was in the proportion
of people with healed ulcers, the area of the ulcers or the time for
healing.
Effects of interventions
See: Summary of findings for the main comparisonOral aspirin
for venous leg ulcers
Both included RCTs analysed the ulcer healing time, but reported
it using different outcome measures. The interventions that were
studied in the two trials that reported relevant outcomes for this
review were too heterogenous to allow pooling of outcomes data.
We therefore reported the trial results for each trial separately.
Primary outcomes
Time to complete ulcer healing
The del Río Solá 2012 trial followed the people until the healing
of their ulcers and reported the average time for healing was 12
weeks in the aspirin group and 22 weeks in the control group, P
values and confidence intervals were not reported Table 1.
Rate of changes in the area of the ulcer in the trial period
The Layton 1994 stopped the trial in the fourth month and re-
ported this outcome: by four months, ulcer area had reduced (by
6.5 cm², a 39.4% reduction) in the aspirin group compared with
no reduction in ulcer area in the control group (P value < 0.002;
Summary of findings for the main comparison).
Proportion of ulcers healed in the trial period
The Layton 1994 trial reported this outcome: a higher proportion
of the ulcers (38%) in the aspirin group had completely healed in
the trial period compared with none in the control group (P value
< 0.007; Summary of findings for the main comparison).
Proportion of people with ulcers healed in the trial period
The del Río Solá 2012 trial reported that there was no real differ-
ence between the proportion of people with ulcers healed in the
aspirin group (74%, 17 out of 23 people) and in the control group
(75%, 21 out of 28 people; Table 1), (RR 0.99, 95% CI 0.71 to
1.36; Analysis 1.1).
Major bleeding (haemorrhagic stroke, gastric bleeding, any
bleeding requiring blood transfusion, any bleeding causing
hospitalisation)
The del Río Solá 2012 trial reported two hospitalisations, in ad-
dition to two other withdrawals, but did not specify the cause or
the group assignment of the participants who withdrew (Table 1).
The Layton 1994 trial reported that no side effects were experi-
enced (Table 1).
Secondary outcomes
Pain relief
Neither study reported pain relief.
Mortality
The Layton 1994 trial reported that no side effects were experi-
enced.
The del Río Solá 2012 trial reported that two people needed hos-
pitalisation and had to be withdrawn from the trial (in addition
to two other withdrawals), but they didn’t report the reason for
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hospitalisation or their group assignment. The authors did not
report other adverse events.
Adverse events
The Layton 1994 trial reported that participants had no adverse
effects, but did not explain how this was established. The del Río
Solá 2012 trial did not report adverse events.
Ulcer recurrence
The del Río Solá 2012 trial reported the average time of ulcer
recurrence was 16.33 days (SD: 7.5) in the control group and 39
days (SD: 6.0) in the aspirin group (P = 0.007).
Layton 1994 did not report recurrence.
D I S C U S S I O N
Summary of main results
Aspirin has been used as medication since 1899 and its phar-
macodynamic properties as an anti-inflammatory, analgesic, an-
tipyretic, and inhibitor of both platelet aggregation and biosyn-
thesis of prostaglandins, have been well studied. VLUs are asso-
ciated with venous stasis, inflammation and necrosis; so some of
the properties of aspirin may be useful for patients with VLUs.
We searched extensively in seven different databases, using an ap-
propriate search strategy for each one, to identify studies that had
analysed the effect of aspirin on healing of VLUs. This review
intended to summarize the effect of oral aspirin in treatment of
VLUs; our searches identified no previous reviews and only two
clinical trials that could be included, del Río Solá 2012 with 51
participants, and Layton 1994 with 20 participants. Both studies
used the same intervention (oral aspirin 300 mg/day) and had the
objective of evaluating the effects of oral aspirin on the healing of
VLUs, however they used different outcome measurements. The
Layton 1994 trial compared the average reduction in ulcer area
in the second and fourth months, while the del Río Solá 2012
trial compared the average time for complete healing of the ul-
cer. The conclusions of both studies favoured the aspirin group:
Layton 1994 showed a significant reduction in ulcer area in the
fourth month of treatment and del Río Solá 2012 showed a signif-
icant reduction in the time required for complete healing of ulcers.
However the two studies included very few participants, a total of
71, and the differences in the outcomes measurements prevented
meta-analysis. The evidence was downgraded to low quality due
to the potential for selection bias and imprecision in the results,
thus there is uncertainty around the effect estimates.
Overall completeness and applicability of
evidence
There was scant evidence available to assess the benefits of 300,mg
aspirin to heal people with venous leg ulcers.The small number,
small size and differing outcome measurements of the two in-
cluded trials meant that there was insufficient evidence for us to
draw meaningful conclusions about the use of oral aspirin in the
treatment of VLUs.
The benefits and harms of aspirin varies with its plasmatic level.
Aspirin blood concentration from 50 to 300 mcg/ml are sufficient
for most of its therapeutic effects and doses greater than 200 mcg/
ml increase the risks for adverse events. Nowadays aspirin is used
to treat many vascular conditions such as, ischemic stroke, angina
pectoris, myocardial infarction, revascularization procedures, etc,
with doses that vary from 50 to 325 mg/day. Both studies included
in this review used 300 mg aspirin daily, however, the ideal dose
for each clinical condition remains in debate (Cappelleri 1995;
Dalen 2006).
Layton 1994, did not report any characteristics of the population
included in his study; del Río Solá 2012 included 51 patients, 29
women and 22menwith mean age of 60 years ranging from 36-86
years old. The study excluded patients with co morbidities such as
diabetes mellitus, rheumatoid arthritis, peripheral arterial disease
and neurologic disease. The characteristics of this population is in
concordance with the populations described in the epidemiologic
studies of chronic venous insufficiency (Beebe-Dimmer 2005).
Quality of the evidence
Only low quality evidence was available from two trials and both
the RCTs that were eligible for inclusion in the review had an
unclear or high risk of bias for most domains (allocation con-
cealment, blinding of participants and personnel, incomplete out-
come data and other biases). Due to the lack of reliable evidence,
we are unable to draw conclusions about the benefits and harms
of oral daily aspirin as an adjunct to compression in VLU healing
or recurrence. We graded the overall quality of the evidence as
low, indicating that future research is likely to have an important
influence on the effect estimates.
Potential biases in the review process
We are confident that the broad literature search used in this review
has captured most of the relevant literature, and minimised the
likelihood that we have missed any relevant trials. Two review
authors independently selected trials, extracted data, and assessed
risk of bias, in order to minimise bias. Due to the differences in
reporting of outcome measures between the trials, we could not
conduct the planned meta-analysis.
Agreements and disagreements with other
studies or reviews
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This is the first review of randomised studies that address this
question, as far as we are aware. The treatment of VLUs can be
frustrating for physicians and people with ulcers because these
kinds of ulcers have a tendency to recur and become chronic. Some
therapies are already well established, such as compression and rest
with elevated legs (O’Meara 2012). On the basis of recent research
that showed the importance of inflammation in the development
of ulcers, new therapies using anti-inflammatory drugs have been
evaluated, including pentoxifylline (Jull 2007), prostaglandins (
Rudofsky 1989), and prostacyclin analogues (Werner-Schlenzka
1994). These studies often describe benefits, but like the studies
included in this review, they have only included small numbers of
participants.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Two small studies showed that aspirin may improve the healing of
venous leg ulcers (VLUs). Given that these studies were at moder-
ate (to high) risk of bias and did not report on other important ad-
verse events, such as bleeding, it may be prudent to limit the use of
aspirin to aid healing in this population until evidence of benefit,
and of no harm, is available. The conclusions we can draw in our
systematic review are limited by the quality and number of trials
that met our inclusion criteria, and lack of reporting of important
outcomes. The trials we identified were susceptible to bias, and
hampered by inadequate reporting and small sample sizes, which
may have hidden real benefits.
Implications for research
Although the role of inflammation in the development of VLUs
is well documented, this review has shown that there is very little
research on the benefits and harms of aspirin in their treatment.
Consequently, we still have insufficient high-quality evidence to
make definitive conclusions about the effectiveness and safety of
aspirin for people with this condition. Further high quality re-
search is required before definitive conclusions can be made about
the benefits of aspirin as an adjunct to compression in people with
VLUs. Future trials should clearly report baseline participant char-
acteristics and conform to the CONSORT 2010 recommenda-
tions with sufficient power to detect a true treatment effect.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
del Río Solá 2012
Methods Prospective RCT
Participants 51 people with venous leg ulcers (29 women and 22 men); mean age of 60 years (range
from 36-86)
Interventions Intervention Group (n = 23): aspirin 300 mg/day
Control Group (n = 28): no placebo treatment
Compression therapy was used for both groups
Outcomes • Number of people with ulcers completely healed
• Time for complete ulcer healing
• Number of ulcer recurrences
• Time until ulcer recurrence
Notes Excluded patients with diabetesmellitus, rheumatoid arthritis, peripheral arterial disease,
neurologic disease, previous or concomitant therapy with aspirin, and ulcers ≤ 2 cm
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Performed by an independent researcher using a computer pro-
gram
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The comparison was conducted between intervention and non-
intervention, blinding of participants and personnel was not
possible in this case
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The participants were evaluatedweekly using a specific form, but
no information was provided about blinding of the personnel
who did this work
Incomplete outcome data (attrition bias)
All outcomes
High risk There were 4 withdrawals; 2 people were hospitalised and 2 peo-
ple opted for treatment in another service. The authors did not
describe the cause of the hospitalisations or group assignment
of the withdrawn participants
Selective reporting (reporting bias) Low risk The only primary prespecified outcome reported was the influ-
ence of aspirin on the rate of ulcer healing
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del Río Solá 2012 (Continued)
Other bias High risk The individual data for each participant were not presented
There were some inconsistencies and mistakes in the reported
results (the same outcome measures were presented with differ-
ent values in the text and in the tables)
Layton 1994
Methods Prospective double-blind and placebo-controlled RCT
Participants 20 people with chronic venous leg ulcers
Interventions Intervention Group (n = 10): aspirin 300 mg/day
Control Group (n = 10): placebo
Outcomes • Reduction of ulcer surface area in the second and fourth months.
• Percentage of ulcers healed completely in trial period
Notes People with ulcers ≤ 2 cm and previous or concomitant therapy with aspirin were
excluded
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study was described as double-blinded but
the strategy for blinding the patients and
personnel was not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The assessment of ulcer area was conducted
using planimetry of photographs of ulcers
Incomplete outcome data (attrition bias)
All outcomes
High risk The individual data from each participant
were not presented
Selective reporting (reporting bias) High risk Both the primary prespecified outcomes
were reported (the influence of aspirin on
the reduction of ulcer surface area and per-
centage of ulcers healed completely in trial
period)
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Layton 1994 (Continued)
Other bias High risk The prevalence of co morbidities (diabetes,
arterial hypertension) that could influence
the ulcer healing was not reported
Abbreviation
RCT: randomized controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ibbotson 1995 This trial used the same participants and data as the Layton 1994 trial to evaluate some haemostatic parameters in
people with venous leg ulcers taking oral aspirin. This group of people with leg ulcers was compared with a control
group of healthy people
Characteristics of ongoing studies [ordered by study ID]
ACTRN12614000293662
Trial name or title Clinical effectiveness of aspirin as an adjunct to compression therapy in healing chronic venous leg ulcers: a
randomised double-blinded placebo-controlled trial [the ASPiVLU study]
Methods Prospective, randomised, double blinded, 2 groups in parallel
Participants 268 male or female
Inclusion:
• Age 18 years and older
• Have one or more leg ulcers in the presence of venous insufficiency confirmed by clinical assessment
and/or duplex ultrasound
• The target ulcer (largest ulcer) must be separated from other ulcers by at least 1 cm.
• The target ulcer must have been present for at least six weeks or has prior history of venous ulceration
• The target ulcer has an area ≥1 cm2 to ≤ 20 cm2 as measured by digital planimetry techniques
• An Ankle Brachial Pressure Index [ABPI] measure of ≥ 0.7 mmHg or systolic toe pressure ≥ 50
mmHg to exclude significant arterial insufficiency.
• Participant is able to give informed consent
Exclusion criteria:
• Unable to attend scheduled treatment visits and comply with follow-up contact with study staff
• Aspirin intolerance contraindication to aspirin (according to medical practitioner’s clinical judgement)
• Current, regular aspirin use
• Concurrent use of any other antiplatelet or anticoagulation therapy
• Any existing condition or treatment that is a contraindication to use of aspirin or to participate in the
trial (decision made according to medical practitioner’s clinical judgement)
• Pregnancy or breastfeeding
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ACTRN12614000293662 (Continued)
Interventions Aspirin Arm: will receive oral dose 300 mg enteric coated aspirin daily for 24 weeks
Placebo Arm: will receive oral dose of placebo tablet daily for 24 weeks
All participants will be treated with compression
Outcomes Primary measures:
• Time to healing
• Proof of healing (100% epithelialisation with no scab and no exudate)
Secondary measures:
• Proportion of participants with healed venous leg ulcers
• Recurrence of target ulcer: After healing, participants will be followed up to assess target ulcer
recurrence
• Wound pain score
• Health-related quality of life and wellbeing index
• Adverse Events
• Adherence to compression treatment or secondary prevention compression hosiery once healed
• Adherence to medication
• Serum samples
• Hospitalisation
Starting date March 2015
Contact information carolina.weller@monash.edu
maria.lachina@monash.edu
Notes Financial support from the National Health and Medical Research Council of Australia (APP1069329)
ASPiVLU is registered with Australian New Zealand Clinical Trials Registry. Registration number:
ACTRN12614000293662
Bayer Schering Pharm manufactured the aspirin and matching placebo
NCT02158806
Trial name or title Low dose aspirin for venous leg ulcers (Aspirin4VLU)
Methods Prospective, randomised, double blinded, 2 groups in parallel
Participants Estimated enrolment: 354 patients; 18 years or older; both genders
Inclusion criteria:
• Diagnosed with venous leg ulcers (clinical indications of venous ulceration, ankle brachial Index ≥ 0.8,
and other causative aetiologies ruled out)
• Able to tolerate compression therapy
• Able to provide written informed consent
• Confirmation with participant’s general practitioner that the participant can take low dose aspirin or
placebo
Exclusion criteria:
• Pregnant or breast-feeding women
• History of myocardial infarction, stroke, transient ischaemic attack, angina or significant peripheral
arterial disease
• History of adverse effects related to aspirin use
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NCT02158806 (Continued)
• Currently using aspirin, or other anti-platelet or anticoagulant therapy
• Opinion of screening medical practitioner at National Institute of Health Innovation that participant
has an existing condition or treatment that is a contraindication to use of aspirin or to participation in the
trial
Interventions Experimental: aspirin 150 mg capsule once daily for up to 24 weeks
Placebo comparator: inert capsule matching aspirin capsule once daily for up to 24 weeks
Outcomes Primary outcome measures
• Time to complete healing of reference ulcer (time frame: 24 weeks; designated as safety issue: no)
• Time to event (complete healing defined as intact skin with absence of scab)
Secondary outcome measures
• Proportion of participants with healed venous leg ulcers (time frame: 24 weeks; designated as safety
issue: no)
• Proportion of participants in each arm with completely healed reference ulcers at 24 weeks
• Change in health-related quality of life (generic) (time frame: 24 weeks; designated as safety issue: no)
• Change in generic health-related quality of life (measured by Short Form 36) from baseline to 24 weeks
• Adverse events (time frame: 24 weeks; designated as safety issue: yes)
• Incidence rate ratio of adverse events and serious adverse events at 24 weeks
• Adherence to treatment (time frame: 24 weeks; designated as safety issue: no)
• Adherence to study medication as measured by pill counts at 24 weeks
• Change in health-related quality of life (disease-specific) (time frame: 24 weeks; designated as safety
issue: no)
• Change in disease-specific health-related quality of life (measured by Charing Cross Venous Ulcer
Questionnaire) from baseline to 24 weeks
Starting date January 2015
Contact information Andrew Jull a.jull@auckland.ac.nz;
Chris Bullen c.bullen@auckland.ac.nz
Notes
NCT02333123
Trial name or title Aspirin for Venous Ulcers: Randomised Trial (AVURT)
Methods Phase II randomised, double blind, parallel group, placebo-controlled efficacy trial
Participants Estimated enrolment: 100 patients; >18 years
Inclusion criteria:
• patients with at least one chronic venous leg ulcer
• ulcer area >1cm2
• ABPI 0.8 or greater
• informed consent
Exclusion criteria:
• unable to consent
• unwilling to consent
• foot ulcer
23Oral aspirin for treating venous leg ulcers (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02333123 (Continued)
• leg ulcer of non-venous aetiology
• ABPI <0.8
• regular concomitant aspirin
• previous intolerance or contraindication to aspirin
• prohibited mediation: probenecid, anticoagulants
• known lactose intolerance
• pregnant or lactating women
• already in another study investigating leg ulcer therapy
• previously recruited to trial
Interventions Experimental: aspirin 300 mg once daily for up to 27 weeks
Placebo comparator: placebo once daily for up to 27 weeks
Outcomes Primary outcome measures
• Time to complete healing of reference ulcer
Secondary outcome measures
• Ulcer size
• recurrence of reference ulcer
• adverse events
• ulcer related pain
• treatment compliance (compression and medication)
• resource use (dressings and consultations)
Starting date 2015
Contact information not available
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Oral aspirin versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of people with healed
ulcer
1 51 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.71, 1.36]
2 Time to recurrence (days) 1 51 Mean Difference (IV, Fixed, 95% CI) 22.67 [18.96, 26.38]
Analysis 1.1. Comparison 1 Oral aspirin versus control, Outcome 1 Number of people with healed ulcer.
Review: Oral aspirin for treating venous leg ulcers
Comparison: 1 Oral aspirin versus control
Outcome: 1 Number of people with healed ulcer
Study or subgroup Aspirin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
del R o Sol 2012 17/23 21/28 100.0 % 0.99 [ 0.71, 1.36 ]
Total (95% CI) 23 28 100.0 % 0.99 [ 0.71, 1.36 ]
Total events: 17 (Aspirin), 21 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours Control Favours aspirin
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Analysis 1.2. Comparison 1 Oral aspirin versus control, Outcome 2 Time to recurrence (days).
Review: Oral aspirin for treating venous leg ulcers
Comparison: 1 Oral aspirin versus control
Outcome: 2 Time to recurrence (days)
Study or subgroup Aspirin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[Days] N Mean(SD)[Days] IV,Fixed,95% CI IV,Fixed,95% CI
del R o Sol 2012 23 39 (6) 28 16.33 (7.5) 100.0 % 22.67 [ 18.96, 26.38 ]
Total (95% CI) 23 28 100.0 % 22.67 [ 18.96, 26.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 11.99 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours Control Favours aspirin
A D D I T I O N A L T A B L E S
Table 1. Data extracted from included studies
Study identifi-
cation
Layton del Río Solá
Country United Kingdom Spain
Period Not reported 2001 to 2005
Centres Academic Unit of Dermatology, General Infirmary at
Leeds, West Yorkshire
University Hospital of Valladolid
Source of fund-
ing
Not specified Not specified
Method Method
Study design Prospective randomized, double-blind Prospective randomized trial
Power
calculation
Not described Yes
Method of ran-
domisation
Not described Generated by computer program
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Table 1. Data extracted from included studies (Continued)
Concealment of
allocation
Not described Not described
Number of
participants ran-
domized
20 51
Number of
participants ana-
lyzed
20 47
Number of par-
ticipants ex-
cluded after ran-
domizations
0 0
Number of
participant with-
drawals and rea-
sons
0 4 people; 2 people needed hospitalisation and left the
study and2people opted for treatment in another service
Intention-to-
treat analysis
Yes Yes
Participants Participants
Inclusion criteria People with chronic venous leg ulcer Venous leg ulcer ≥ 2 cm
Ankle-brachial rate < 0.9
No contraindication to taking aspirin
Exclusion crite-
ria
Ulcer diameter < 2 cm
Already taking aspirin, anticoagulants or non-steroidal
anti-inflammatory
Doppler flowmetry ankle-brachial rate < 0.9
People with diabetes mellitus, rheumatoid arthritis, pe-
ripheral arterial disease and neurologic disease
Previous or concomitant therapy with aspirin
Aspirin Control P value Aspirin Control P value
Number of par-
ticipants
10 10 23 28
Age (years) 62.2 years
(mean)
(48-81)
66 years (mean)
(46 - 85)
60.50 years (SD:
12.07)
58.59 years (SD:
16.55)
reported as non
significant
Sex 3 female, 7 male 5 female, 5 male 10 female, 13
male
19 female, 9
male
reported as non
significant
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Table 1. Data extracted from included studies (Continued)
Ulcer duration
before the study
11.4 years
(mean)
(1-24)
10.5 years
(mean)
(2-22)
6-12 months > 12 months
1 Number of ul-
cers
Not reported Not reported Not reported Not reported reported as non
significant
Initial ulcer sur-
face area (cm²)
16.5 cm² (mean)
(2.5-39.5)
14.25 cm²
(mean)
(1.5-48.5)
25.15 cm² 24.87 cm² P=0.944
Signs of ulcer in-
fection
Not reported Not reported Yes, 20 patients Yes, 22 patients P=0.094
Any comorbid-
ity
Not reported Not reported 9 patients 10 patients
Previously
treated
\not reported Not reported 10 patients 20 patients
Interventions Aspirin 300
mg/day
Placebo Aspirin 300
mg/day
No drug treat-
ment
Outcomes Outcomes
Follow-up
(months)
4 months 4 months 42 months mean
(24-61)
42 months mean
(24-61)
2 Withdrawals 0 0 2 people 2 people
Duration of the
study to com-
plete ulcer heal-
ing
Not reported Not reported Not reported 12.4 weeks 16.5 weeks P=0.07 Mann-
Whitney
Healing period Not reported Not reported Not reported Reported
as short in the as-
pirin group
Reported
as short in the as-
pirin group
P=0.04
log-rank test = 3.
90
OR = 0.93 95%
CI 0.25-3.5
Aver-
age time to com-
plete ulcer heal-
ing (weeks)
Not reported Not reported Not reported 12 22 Not reported
Number of par-
tic-
ipants with com-
Not reported Not reported Not reported 17 (74%) 21 (75%) reported as non
significant
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Table 1. Data extracted from included studies (Continued)
plete ulcer heal-
ing in the trial
period
Proportion of ul-
cers healed in the
trial period
38%of the ulcers 0% of the ulcers < 0.007
(x² test)
Not reported Not reported Not reported
Change in ul-
cer areas in the
trial period (sec-
ond month; ul-
cer area cm²)
15.5 cm² (me-
dian)
1 cm² of reduc-
tion
(6.07%of reduc-
tion)
No reduction < 0.01 (x² test) Not reported Not reported Not reported
Reduc-
tion in ulcer size
in the trial period
(fourth month;
ulcer area cm²)
10.0 cm² (me-
dian)
6.5 cm² of reduc-
tion (39.4% of
reduction)
No reduction < 0.002 (x² test) Not reported Not reported Not reported
Improvement as-
sessed by reduc-
tion in ulcer size
52%of the ulcers 26%of the ulcers < 0.007
(x² test)
Not reported Not reported Not reported
Increase in ulcer
size in the trial
period
10%of the ulcers 26%of the ulcers < 0.004
(x² test)
Not reported Not reported Not reported
Ulcers size un-
changed in the
trial period
0% of the ulcers 48%of the ulcers < 0.001
(x2 test)
Not reported Not reported Not reported
Proportion of
participants with
ulcers healed in
the trial period
Not reported Not reported Not reported 17 (74%) 21 (75%) reported as non
significant
Proportion of
participants with
ulcer recurrence
Not reported Not reported Not reported 25% 33.33% 0.74
Average time for
ulcer recurrence
(days)
Not reported Not reported Not reported 39 (SD 6) 16.33 (SD 7.5) P=0.007
Kaplan-Meier
adverse effects 0 0 0 0 Not reported
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1. Layton reported 12 people (60%) and del Rio 28 people (54%) with multiples ulcers but they did not specified the number in
each group
2. del Rio Solá reported that two people were hospitalised and were withdrawn from the study, but did not specify the cause of
hospitalisation or their trial group
A P P E N D I C E S
Appendix 1. Glossary for terms described in the background
Analgesic: substance that provides pain relief.
Anticoagulant: prevents blood clot formation.
Antipyretic: reduces fever.
Chronic venous insufficiency: very poor blood flow or circulation in veins.
Hyperpigmentation: abnormally increased skin colour/pigmentation, such as of the skin or a mucous membrane.
Lipodermatosclerosis: area of hyperpigmentation and induration of the skin in the lower legs caused by inflammation and leakage of
red blood cells into the skin and subcutaneous fat. Seen in people with chronic venous insufficiency.
Oedema: swelling; an abnormal accumulation of fluid beneath the skin, or in one or more of the cavities of the body.
Venous hypertension: high blood pressure in veins
Appendix 2. Search strategies
The Cochrane Wounds Specialised Register
(aspirin or “2-acetyloxy benzoic acid” or acylpyrin or aloxiprinum or colfarit or disopril or aspirin or ecotrin or endosprin or magnecyl
or micristin or polopirin or polopiryna or solprins or solupsan or zorprin or acetysal) AND (INREGISTER)
The Cochrane Central Register of Randomised Controlled Trials (CENTRAL)
#1 MeSH descriptor Leg Ulcer explode all trees
#2 (varicose NEXT ulcer*) or (venous NEXT ulcer*) or (legNEXT ulcer*) or (stasis NEXT ulcer*) or ((lowerNEXT extremit*) NEAR/
2 ulcer*) or (crural NEXT ulcer*) or ulcus cruris:ti,ab,kw
#3 (#1 OR #2)
#4 MeSH descriptor Aspirin explode all trees
#5 (aspirin or “2-acetyloxy benzoic acid” or acylpyrin or aloxiprinum or colfarit or disopril or aspirin or ecotrin or endosprin or magnecyl
or micristin or polopirin or polopiryna or solprins or solupsan or zorprin or acetysal):ti,ab,kw
#6 (#4 OR #5)
#7 (#3 AND #6)
Ovid MEDLINE
1 exp Leg Ulcer/
2 (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris).tw.
3 or/1-2
4 exp Aspirin/
5 (aspirin or 2-acetyloxy benzoic acid or acylpyrin or aloxiprinum or colfarit or disopril or aspirin or ecotrin or endosprin or magnecyl
or micristin or polopirin or polopiryna or solprins or solupsan or zorprin or acetysal).tw.
6 or/4-5
7 3 and 6
8 randomized controlled trial.pt.
9 controlled clinical trial.pt.
10 randomi?ed.ab.
11 placebo.ab.
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12 clinical trials as topic.sh.
13 randomly.ab.
14 trial.ti.
15 or/8-14
16 exp animals/ not humans.sh.
17 15 not 16
18 7 and 17
OVID EMBASE
1 exp leg ulcer/
2 (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris).tw.
3 or/1-2
4 exp acetylsalicylic acid/
5 (aspirin or 2-acetyloxy benzoic acid or acylpyrin or aloxiprinum or colfarit or disopril or ecotrin or endosprin or magnecyl or micristin
or polopirin or polopiryna or solprins or solupsan or zorprin or acetysal).tw.
6 or/4-5
7 3 and 6
8 Randomized controlled trials/
9 Single-Blind Method/
10 Double-Blind Method/
11 Crossover Procedure/
12 (random* or factorial* or crossover* or cross over* or cross-over* or placebo* or assign* or allocat* or volunteer*).ti,ab.
13 (doubl* adj blind*).ti,ab.
14 (singl* adj blind*).ti,ab.
15 or/8-14
16 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
17 human/ or human cell/
18 and/16-17
19 16 not 18
20 15 not 19
21 7 and 20
EBSCO CINAHL
S20 S7 and S19
S19 S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18
S18 MH “Quantitative Studies”
S17 TI placebo* or AB placebo*
S16 MH “Placebos”
S15 TI random* allocat* or AB random* allocat*
S14 MH “Random Assignment”
S13 TI randomi?ed control* trial* or AB randomi?ed control* trial*
S12 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S11 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S10 TI clinic* N1 trial* or AB clinic* N1 trial*
S9 PT Clinical trial
S8 MH “Clinical Trials+”
S7 S3 and S6
S6 S4 or S5
S5 TI ( aspirin or 2-acetyloxy benzoic acid or acylpyrin or aloxiprinum or colfarit or disopril or aspirin or ecotrin or endosprin or
magnecyl or micristin or polopirin or polopiryna or solprins or solupsan or zorprin or acetysal ) or AB ( aspirin or 2-acetyloxy benzoic
acid or acylpyrin or aloxiprinum or colfarit or disopril or aspirin or ecotrin or endosprin or magnecyl or micristin or polopirin or
polopiryna or solprins or solupsan or zorprin or acetysal )
S4 (MH “Aspirin”)
S3 S1 or S2
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S2 TI (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcer cruris or ulcus cruris) or AB (varicose ulcer*
or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcer cruris or ulcus cruris)
S1 (MH “Leg Ulcer+”)
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